Free Trial

Y-mAbs Therapeutics (YMAB) Stock Price, News & Analysis

Y-mAbs Therapeutics logo
$8.55 +0.01 (+0.12%)
Closing price 04:00 PM Eastern
Extended Trading
$8.54 -0.01 (-0.06%)
As of 06:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Y-mAbs Therapeutics Stock (NASDAQ:YMAB)

Key Stats

Today's Range
$8.53
$8.56
50-Day Range
$4.19
$8.55
52-Week Range
$3.55
$16.11
Volume
1.02 million shs
Average Volume
2.05 million shs
Market Capitalization
$388.51 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.62
Consensus Rating
Reduce

Company Overview

Y-mAbs Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
53rd Percentile Overall Score

YMAB MarketRank™: 

Y-mAbs Therapeutics scored higher than 53% of companies evaluated by MarketBeat, and ranked 575th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Y-mAbs Therapeutics has received a consensus rating of Reduce. The company's average rating score is 1.80, and is based on no buy ratings, 8 hold ratings, and 2 sell ratings.

  • Amount of Analyst Coverage

    Y-mAbs Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Y-mAbs Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Y-mAbs Therapeutics are expected to grow in the coming year, from ($0.65) to ($0.59) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Y-mAbs Therapeutics is -17.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Y-mAbs Therapeutics is -17.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Y-mAbs Therapeutics has a P/B Ratio of 4.43. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Y-mAbs Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    6.58% of the float of Y-mAbs Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Y-mAbs Therapeutics has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Y-mAbs Therapeutics has recently decreased by 10.44%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Y-mAbs Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Y-mAbs Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.58% of the float of Y-mAbs Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Y-mAbs Therapeutics has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Y-mAbs Therapeutics has recently decreased by 10.44%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Y-mAbs Therapeutics has a news sentiment score of 1.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.98 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Y-mAbs Therapeutics this week, compared to 4 articles on an average week.
  • MarketBeat Follows

    Only 4 people have added Y-mAbs Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -56% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Y-mAbs Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    19.70% of the stock of Y-mAbs Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    70.85% of the stock of Y-mAbs Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Y-mAbs Therapeutics' insider trading history.
Receive YMAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Y-mAbs Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

YMAB Stock News Headlines

Brokerages Set Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) PT at $9.62
Musk’s Project Colossus could mint millionaires
I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.tc pixel
See More Headlines

YMAB Stock Analysis - Frequently Asked Questions

Y-mAbs Therapeutics' stock was trading at $7.83 at the beginning of 2025. Since then, YMAB shares have increased by 9.2% and is now trading at $8.55.

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) posted its quarterly earnings results on Friday, August, 8th. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.20. The business had revenue of $19.52 million for the quarter, compared to the consensus estimate of $18.40 million. Y-mAbs Therapeutics had a negative net margin of 26.03% and a negative trailing twelve-month return on equity of 24.60%.

Y-mAbs Therapeutics (YMAB) raised $80 million in an IPO on Friday, September 21st 2018. The company issued 5,300,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Canaccord Genuity served as the underwriters for the IPO and BTIG was co-manager.

Y-mAbs Therapeutics' top institutional investors include Acorn Capital Advisors LLC (7.52%), Nantahala Capital Management LLC (0.77%), Stonepine Capital Management LLC (0.63%) and Bank of America Corp DE (0.60%). Insiders that own company stock include Biotech Aps Wg, Johan Wedell-Wedellsborg, Bo Kruse, Thomas Gad, Michael J Rossi, Vignesh Rajah and Joris Wilms.
View institutional ownership trends
.

Shares of YMAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Y-mAbs Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), e.l.f. Beauty (ELF), Adobe (ADBE) and Jabil (JBL).

Company Calendar

Last Earnings
8/08/2025
Today
8/27/2025
Next Earnings (Estimated)
11/14/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:YMAB
CIK
1722964
Fax
N/A
Employees
150
Year Founded
N/A

Price Target and Rating

High Price Target
$17.00
Low Price Target
$3.00
Potential Upside/Downside
+12.5%
Consensus Rating
Reduce
Rating Score (0-4)
1.80
Research Coverage
10 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.50)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$29.67 million
Net Margins
-26.03%
Pretax Margin
-26.49%
Return on Equity
-24.60%
Return on Assets
-18.89%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.00
Quick Ratio
3.58

Sales & Book Value

Annual Sales
$87.68 million
Price / Sales
4.43
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.93 per share
Price / Book
4.43

Miscellaneous

Outstanding Shares
45,440,000
Free Float
36,487,000
Market Cap
$388.51 million
Optionable
Optionable
Beta
0.57

Social Links

Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

This page (NASDAQ:YMAB) was last updated on 8/27/2025 by MarketBeat.com Staff
From Our Partners